Heterozygous missense variants of SPTBN2 are a frequent cause of congenital cerebellar ataxia by Nicita, Francesco et al.
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/cge.13562 
 
Heterozygous missense variants of SPTBN2 are a frequent cause of congenital cerebellar ataxia  
 
Francesco Nicita1#, Marta Nardella1#, Emanuele Bellacchio2, Paolo Alfieri3, Gaetano Terrone4, 
Giorgia Piccini3, Federica Graziola5, Claudio Pignata4, Alessandro Capuano5, Enrico Bertini1 and 
Ginevra Zanni1* 
 
1 Unit of Neuromuscular and Neurodegenerative diseases, Department of Neurosciences, Bambino 
Gesù Children's Hospital, Rome, Italy 
2 Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, Rome, Italy 
3 Unit of Child Neuropsychiatry, Department of Neurosciences, Bambino Gesù Children's Hospital, 
Rome, Italy 
4 Department of Translational Medical Sciences, Section of Pediatrics, University of Naples 
Federico II, Naples, Italy 
5 Unit of Neurology, Department of Neurosciences, Bambino Gesù Children's Hospital, Rome, Italy 
 
# These authors have contributed equally to this work 
 
* Corresponding author:  
Ginevra Zanni MD, PhD 
Bambino Gesù Children's Hospital, Rome, Italy.  
Email: ginevra.zanni@opbg.net 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
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ABSTRACT  
Heterozygous missense variants in the SPTBN2 gene, encoding the non‐erythrocytic beta spectrin 2 
subunit (beta‐III spectrin), have been identified in autosomal dominant spinocerebellar ataxia type 5 
(SCA5), a rare adult-onset neurodegenerative disorder characterized by progressive cerebellar 
ataxia, whereas homozygous loss of function variants in SPTBN2 have been associated with early 
onset cerebellar ataxia and global developmental delay (SCAR14). Recently, heterozygous SPTBN2 
missense variants have been identified in a few patients with an early-onset ataxic phenotype.  We 
report five patients with non-progressive congenital ataxia and psychomotor delay, 4/5 harboring  
novel heterozygous missense variants in SPTBN2 and one patient with compound heterozygous 
SPTBN2 variants.  With an overall prevalence of 5% in our cohort of unrelated patients screened by 
targeted next generation sequencing (NGS) for congenital or early-onset cerebellar ataxia, this study  
indicates that both dominant and recessive mutations of SPTBN2 together with CACNA1A and 
ITPR1, are a frequent cause of early-onset/congenital non-progressive ataxia and that their 
screening should be implemented in this subgroup of disorders. 
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INTRODUCTION 
Congenital ataxias account for about 10% of non-progressive infantile encephalopathies and are 
characterized by severe neonatal hypotonia and developmental delay, followed by cerebellar ataxia 
in the first years of life. They are generally classified into pure cerebellar and syndromic forms and 
their inheritance can be autosomal recessive autosomal dominant or X‐linked recessive (reviewed 
by [1,2]). More than 20 genes are known to date (see supplemental Table S1). Homozygous loss of 
function mutations of SPTBN2 have been identified in four families with early-onset cerebellar 
ataxia associated with cognitive impairment, eye movements abnormalities and variable additional 
neurological signs, defined as autosomal recessive spinocerebellar ataxia 14 (SCAR14; 
MIM#615386) [3-6]. Heterozygous missense variants of SPTBN2 have been initially associated to 
autosomal dominant spinocerebellar ataxia 5 (SCA5; MIM#600224) characterized by a slowly 
progressive cerebellar syndrome with downbeat nystagmus and tremor, beginning in the third 
decade with a tendency toward anticipation in later generations [7-11]. The identification of 3 
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unrelated cases of early-onset cerebellar ataxia and developmental delay carrying the same de novo 
pathogenic variant (p.R480W) in SPTBN2 has challenged the previous SCA5/SCAR14 genotype-
phenotype correlation [12-15]. We used targeted next generation sequencing in 100 unrelated 
patients  with non-progressive congenital or early onset ataxia associated with cerebellar  atrophy. . 
 
 
 
 
MATERIAL and METHODS 
Clinical reports  
The clinical and neuroradiological features of the five probands (Figure 1, Table 1 and 
Supplemental files ): congenital onset (within the first months of life), nonprogressive cerebellar 
symptoms (nystagmus, ataxia, hypotonia) and developmental delay, are almost constant findings. 
For detailed neuropsychological profiling of patients 1 and 5 (see supplemental files and Table S2).  
 
Next-Generation Sequencing and Bioinformatic Analysis 
All samples (from 100 index patients: 87 sporadic cases, 8 probands with autosomal dominant, 4 
with autosomal recessive and one with X-linked inheritance) were included in a next-generation 
sequencing (NGS) panel of genes whose mutations are causative of various forms of cerebellar 
ataxias (Table S3), including all known SCA genes. Genomic DNA was extracted from peripheral 
blood of the patients and their parents. Informed consent was obtained from all participating 
subjects according to the Declaration of Helsinki. The panel was designed using Nextera technology 
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on a MiSeq platform (Illumina, San Diego, CA, USA), following the manufacturer’s protocol, with 
expected coverage of 99% of the targeted genomic regions. Mapping of sequences against the hg19 
reference genome was performed by Bowtie2. Bioinformatic tools HaplotypeCaller (GATK ver. 
4.3) and ANNOVAR were used to call and annotate the variants, respectively. Subsequent filtering 
allowed to exclude intronic variants, synonymous variants not affecting splicing, and variants with 
frequency >1% in human variation databases. Segregation was verified by Sanger sequencing in the 
families. Accession numbers are as follows: human SPTBN2 mRNA: NM_006946; human 
SPTBN2 protein: NP_008877. The pathogenicity of the identified missense variant was 
investigated using PolyPhen-2, SIFT, Mutation Assessor, and CADD, while conservation of the 
affected residue was assessed by ClustalW2 (http:// www.ebi.ac.uk/Tools/msa/clustalw2/). We 
filtered rare SPTBN2 variants in 15/100 ataxic patients (a list of all SPTBN2 variants found in our 
screening is available as supplemental Table S4); only one third (5/15) of the variants were 
confirmed to be pathogenic (highly conserved, predicted to be damaging by in silico tools and 
molecular modeling), after segregation analysis and careful clinical (and in some case MRI) 
evaluation by two experienced pediatric neurologists, of carrier parents. 
Modelling  
The p.T62I and p.F160C mutations were mapped on the PDB structure 6ANU (cryo-electron 
microscopy structure of F-actin complexed with spectrin beta chain). The p.Y272H mutation was 
mapped on the conformer 4 of the PDB structure 1WYQ (NMR structure of the second CH domain 
of human spectrin beta chain). To model the p.R437W and p.R437Q mutations, the homology 
model of SPTBN2 spectrin repeats 1-3 was built employing the following procedure. The amino 
acid residues 305-638 of SPTBN2 and the residues of the ROD domain of alpha-actinin from the 
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PDB entry 1HCI (used as the template structure), were aligned (the two sequences share 33% amino 
acid identity; Supplementary file 1). All side chain atoms in the template structure were deleted, the 
amino acids were renamed and renumbered to the corresponding human SPTBN2 residues 
according to the above pairwise sequence alignment, and the modified PDB structure file was 
parsed to SIDEpro [16] for side chain reconstruction. 
 
RESULTS 
Genetic data 
Six novel mutations in SPTBN2 were detected. In particular, four patients harbored heterozygous 
missense variants (NM_006946): c.185C>T;p.T62I, c.479T>G;p.F160C, c.1309C>T;p.R437W, and 
c.1310G>A;p.R437Q and one patient harbored compound heterozygous variants (a nonsense 
c.6267G>A; p.W2065* and a missense c.888T>C; p.Y272H) (Figure 2, Table 1) . Segregation 
analysis demonstrated a de novo origin of the mutations in three cases (patient 1, 2 and 3) whereas 
in one case (patient 4) segregation analysis could not be completed because the father was not alive. 
All mutations are predicted deleterious or probably damaging by in silico prediction tools. None of 
the six mutations have been reported in available databases (i.e., dbSNP146, 1000 Genomes, ExAC 
and GnomAD). 
 
Molecular Modeling  
The p.T62I and p.F160C pathogenic variants fall in the first Calponin-homology (CH) domain of 
SPTBN2 (NP_008877) affecting a highly conserved residue. The replacement of Thr62 with an 
isoleucine residue introduces a novel hydrophobic interaction with Trp154, which modify the 
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interface of the CH-1 domain and actin (Fig. 3B). The replacement of Phe160 (highly conserved) 
with a cysteine causes the loss of the hydrophobic interactions with Trp66 and Leu98 (Fig. 3C), 
modifying also in this case the interface of the CH-1 domain with actin. The p.Y272H mutation 
affects a highly conserved residue and disrupts the hydrophobic interactions with nearby residues in 
the second CH domain of SPTBN2 (Fig. 3D). Superposition of the SPTBN2 CH-2 domain with the 
CH2 domain of human alpha-actinin, which, like SPTBN2 also presents two CH domains arranged 
in tandem, suggests that the Y272H amino acid substitution likely perturbs the interface between 
the two CH domains and possibly their mutual three-dimensional arrangements. The p.R437W or 
p.R437Q mutation implies the replacement of the cationic and highly conserved arginine 437 with 
the aromatic and large tryptophan (W) or the polar glutamine (Q) residue in a region that has 
structural importance for the second spectrin repeat (Fig. 3E). Both the tryptophan and glutamine 
residues should cause important reorganizations in the structure of the spectrin repeat 2 also 
affecting its arrangement with the flanking repeats (spectrin repeats 1 and 3). The p.W2065* 
mutation causes the loss of a functional domain of SPTBN2 (Fig. 3A). Based on conservation and 
structural analysis, all the mutations presented in this work are expected to have important impacts 
on functional regions of the SPTBN2 protein, providing a basis for rationalizing their pathogenic 
effects. 
 
DISCUSSION 
Spectrins are heterotetrameric cytoskeletal membrane proteins composed of two main alpha 
subunits (SPTA1, SPTAN1) and five beta subunits (SPTB, SPTBN1, SPTBN2, SPTBN4, SPTBN5) 
(reviewed by [17]) . The non‐erythrocytic beta spectrin 2 subunit (beta‐III spectrin) is a 2,391-
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amino acid protein encoded by SPTBN2 (11q13.2) and expressed throughout the soma and dendritic 
tree of cerebellar Purkinje cells. SPTBN2 is required for the maintenance of dendritic architecture, 
and for the trafficking and stabilization of several membrane proteins: Ankyrin-R, cell adhesion 
proteins, voltage-gated sodium channels, glutamate receptors (mGluR1) and transporters (EAAT4) 
[18]. It contains the actin/ARP1 binding site at the N-terminal (calponin-homology domains), 17 
spectrin repeats involved in the formation of the heterotetrameric ±-² -spectrin complex and a 
pleckstrin homology (PH) domain which binds phosphatidylinositol lipids, at the C-terminal [19]. 
Loss of SPTBN2 in the mouse mutant results in altered dendritic morphology and density, changes 
in Purkinje cells intrinsic excitability: reduced sodium currents and deficits in glutamatergic 
neurotransmission. [20-22].  
To date, three cases of dominant SPTBN2 (p.R480W) mutations and four cases of homozygous 
recessive mutations have been reported in early-onset ataxia (Figure S1). In a recent targeted exome 
analysis of patients with ataxic phenotypes, de novo or dominant SPTBN2 mutations were identified 
in 4/88 (4,5%) two of them presenting with infantile onset ataxia and developmental delay [23]. 
Here we show novel pathogenic SPTBN2 variants in 5% of our cohort of patients with congenital or 
early-onset non-progressive ataxia; of note that only one third (5/15) of the rare SPTBN2 variants 
identified in our study were confirmed to be pathogenic.  The five novel  pathogenic missense 
variants localized in the actin binding domain or in the spectrin repeats domains of SPTBN2 and 
one stop variant localized in the PH domain of the protein. Thermodynamic changes caused by 
different mutations may affect the overall dimerization capability of the protein. The hotspot 
R480W mutation, located in the second spectrin repeat domain (as the R437Q and R437W variants 
identified in the present study) has been predicted to increase protein stability, whereas SCA5-
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related T472M found in the same domain or L253P found in the actin binding domain were either 
neutral or destabilizing the protein [14]. Yet the molecular mechanisms for differences in timing of 
onset, progression, mode of inheritance and presence of cognitive deficits in ataxic patients, remain 
unknown. Interestingly, the two brothers carrying a homozygous missense mutation reported by [6] 
and patient 5, carrying a nonsense and a missense variant, appear to have a milder phenotype with 
normal cognitive development (Supplemental file 2 and Table S2) if compared with previously 
reported SCAR14 patients with homozygous loss of function mutations [3-5]. Similar frequencies 
have been observed for mutations in other SCA-associated loci such as ITPR1 [24, 25, 26], 
CACNA1A [27], whereas both autosomal recessive and dominant modes of inheritance associated 
with neurodevelopmental and/or neurodegenerative features have been reported in   KCNC3 [28] or 
GRM1 [29, 30] mutated families. The challenge will be to decipher subtle changes underpinning 
Purkinje cells dysfunction both in early and later stages of these various forms of ataxia. This study 
further delineates the clinical, mutational and epidemiological spectrum of congenital and early 
onset SPTBN2-related ataxias and suggest that screening of SPTBN2 should be implemented in this 
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LEGEND FOR FIGURES 
Figure 1A-J: Brain MRI of patient 1 at the age of 2y8mo (A,F), patient 2 at the age of 10y (B,G), 
patient 3  at the age of 11mo (C) and 2y10mo (H; with artefacts), patient 4 at the age of 16y5mo 
(D,I), and patient 5 at the age of 2y8mo (E,J). Severe atrophy of cerebellar hemispheres and vermis 
is evident in patients 1-4; a milder atrophy in the upper cerebellar vermis is present in patient 5 with 
compound heterozygous SPTBN2 variants (white arrow in J). No abnormalities of the pons, corpus 
callosum, cerebral white or grey matter are observed in all patients.    
  
Figure 2: Pedigree structure and sequencing chromatograms of SPTBN2 mutations identified by 
targeted resequencing in the affected individuals and corresponding wild‐type sequences in 
unaffected parents. Vertical arrows indicate the site of nucleotide exchange. 
 
Figure 3A-E: Structural analysis and sequence conservation around the sites affected by mutations 
in SPTBN2. (A) Scheme of SPTBN2 protein indicating the mutations presented in this work. (B) 
Structure of SPTBN2 in complex with actin (PDB 6ANU) showing the site of the p.T62I mutation. 
(C) Crystal structure of SPTBN2 in complex with actin (PDB 6ANU) highlighting the site of the 
p.F160C mutation. (D) NMR structure of the CH-2 domain of SPTBN2 (PDB 1WYQ , blue 
ribbons) superposed on the structure of the CH1-CH2 domains of human alpha-actinin (PDB 2EYI, 
white ribbons) indicating the site of the p.Y272H mutation. (E) Homology model of SPTBN2 
spectrin repeats 1-3, showing the site of the p.R437W mutation. In the protein structures, residues 
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interacting with the amino acids affected by mutations are shown (for clarity not all residues are 
displayed). In the sequence alignments, the grayed columns represent invariant residues. 
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Figure 1A-J: Brain MRI of patient 1 at the age of 2y8mo (A,F), patient 2 at the age of 10y (B,G), patient 3 
 at the age of 11mo (C) and 2y10mo (H; with artefacts), patient 4 at the age of 16y5mo (D,I), and patient 5 
at the age of 2y8mo (E,J). Severe atrophy of cerebellar hemispheres and vermis is evident in patients 1-4; a 
milder atrophy in the upper cerebellar vermis is present in patient 5 with compound heterozygous SPTBN2 
variants (white arrow in J). No abnormalities of the pons, corpus callosum, cerebral white or grey matter are 
observed in all patients.   
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Figure 2: Pedigree structure and sequencing chromatograms of SPTBN2 mutations identified by targeted 
resequencing in the affected individuals and corresponding wild‐type sequences in unaffected parents. 
Vertical arrows indicate the site of nucleotide exchange. 
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Figure 3A-E: Structural analysis and sequence conservation around the sites affected by mutations in 
SPTBN2. (A) Scheme of SPTBN2 protein indicating the mutations presented in this work. (B) Structure of 
SPTBN2 in complex with actin (PDB 6ANU) showing the site of the p.T62I mutation. (C) Crystal structure of 
SPTBN2 in complex with actin (PDB 6ANU) highlighting the site of the p.F160C mutation. (D) NMR structure 
of the CH-2 domain of SPTBN2 (PDB 1WYQ , blue ribbons) superposed on the structure of the CH1-CH2 
domains of human alpha-actinin (PDB 2EYI, white ribbons) indicating the site of the p.Y272H mutation. (E) 
Homology model of SPTBN2 spectrin repeats 1-3, showing the site of the p.R437W mutation. In the protein 
structures, residues interacting with the amino acids affected by mutations are shown (for clarity not all 
residues are displayed). In the sequence alignments, the grayed columns represent invariant residues. 
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Table 1: Summary of the clinical, genetic and neuroradiological features of the reported patients
Patient 1 2 3 4 5 
Sex, Age F, 8 years M, 18 years M, 5 years F, 18 years F, 9 years
SPTBN2 variant c.1309C>T c.1310G>A c.479T>G c.185C>T c.888T>C; c.6267G>A;
Protein p.R437W p.R437Q p.F160C p.T62I p.Y272H;p.W2065*
Domain 2nd SPEC 2nd SPEC ABD ABD 17th SPEC, PH
Age of onset 10 mo 5 mo 5 mo 8 mo 12 mo
First 
sign/symptom at 
onset
Psychomotor 
delay
Hypotonia Psychomotor 
delay and 
strabismus
Psychomotor 
delay
Microcephaly
Motor delay
Sitting 
unsupported
1 y 10 mo 13 mo 1 y 8 mo
Walk (ataxic) 
unassisted
5 y 2 y Not acquired 10 y 2 y 4 mo
First words 2 y 6 mo 1 y Not acquired 3 y 1 y 6 mo
Ocular 
anomalies
- Nystagmus 
(horizontal)
Strabismus Nystagmus 
(horizontal and 
vertical)
-
Congenital 
hypotonia
+ + + + + (mild)
Pyramidal signs - + (increased OTR) - - -
Tremor - + (intention tremor) - - -
Dystonia - - - - -
Facial myokymia - - - - -
Bulbar 
dysfunction
- - - - -
Cognitive delay + + + + -
Behavioral 
problems
- - - - -
Additional 
findings
- - - Mild 
bradykinesia
-
Cerebellar 
atrophy
+ + + + + (mild)
Progression of 
atrophy
NA + + NA NA
Additional MRI 
findings
- - - - -
Course Non progressive
Non progressive Non progressive Non progressive Non progressive 
SPEC= Spectrin repeats; ABD= Actin binding domain; n.d = not determined in the father, absent in the 
mother; OTR= osteotendineous reflexes; PH= Pleckstrin homology domain
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